CC-930JNK inhibitor,potent and selective CAS# 899805-25-5 |
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- CC-401 hydrochloride
Catalog No.:BCC1458
CAS No.:1438391-30-0
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 899805-25-5 | SDF | Download SDF |
PubChem ID | 11597537 | Appearance | Powder |
Formula | C21H23F3N6O2 | M.Wt | 448.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Tanzisertib | ||
Solubility | DMSO : ≥ 33 mg/mL (73.59 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol | ||
SMILES | C1CC(CCC1NC2=NC=C3C(=N2)N(C(=N3)NC4=C(C=C(C=C4F)F)F)C5CCOC5)O | ||
Standard InChIKey | IBGLGMOPHJQDJB-MOKVOYLWSA-N | ||
Standard InChI | InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | CC-930 is a potent JNK1/JNK2/JNK3 inhibitor with IC50 values of 61/7/6 nM, respectively, and used for the treatment of fibrotic and infammatory indications.In Vitro:CC-930 inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1]. CC-930 (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes[2]. CC-930 blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis[3].In Vivo:CC-930 (10 and 30 mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model[1]. CC-930 (150 mg/kg) prevents the development of fibrosis in different models, but can also induce the regression of pre-existing fibrosis[3]. References: |
CC-930 Dilution Calculator
CC-930 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.23 mL | 11.1498 mL | 22.2995 mL | 44.5991 mL | 55.7488 mL |
5 mM | 0.446 mL | 2.23 mL | 4.4599 mL | 8.9198 mL | 11.1498 mL |
10 mM | 0.223 mL | 1.115 mL | 2.23 mL | 4.4599 mL | 5.5749 mL |
50 mM | 0.0446 mL | 0.223 mL | 0.446 mL | 0.892 mL | 1.115 mL |
100 mM | 0.0223 mL | 0.1115 mL | 0.223 mL | 0.446 mL | 0.5575 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CC-930 is a potent and selective inhibitor of JNK1/JNK2/JNK3 with IC50 values of 61 nM, 7 nM and 6 nM respectively. [1]
JNKs (c-Jun N-terminal kinases) belong to kinases which were originally indentified. They bind to c-Jun then phosphorylate it on Ser-63 and Ser-73 which located in its transcriptional activation domain. JNKs belong to MAPK family. They contain ten isforms encoded by three genes: JNK1, JNK2 and JNK3. They are 46 KD or 55 KD protein. They play an important role in stress stimuli, such as heat shock, cytokines, and osmotic shock. They are also responsive to the cellular apoptosis pathway and T cell differentiation. They are activated through a dual phosphorylation of Thr and Tyr residues within a Thr-Pro-Tyr motif which located in kinase subdomain. JNKs modify the activity of many proteins that act in the nucleus reside or at the mitochondria. JNKs activate the downstream molecules which include p53, c-Jun, ELK1, SMAD4 and HSF1. JNKs regulate several important cellular functions, such as cell growth, survival, differentiation and apoptosis.[2]
CC-930 kinetically competitive with ATP in the phosphorylation of the substrate c-Jun against all isoforms of JNK with Ki values of 44 ± 3 nM (JNK1), 6.2 ± 0.6 nM and IC50 value of 5 nm for JNK3. EGFR is the only non-MAP kinase which inhibited more than 50% at 3 M. It did not inhibit greater than 50% against 22 diverse non-kinase enzymes at 10 M.[1] CC-930 reduced the phosphorylation of c-Jun the stimulated by TGF β at 1 μM which is a clinically relevant concentration in fi broblasts[3] CC-930 also was showed the potent antifibrotic founctions in the TSK1 model. CC-930 reduced hypodermal thickening with a dose-dependent manner by up to 85±4% in TSK1 mice.[3] CC-930 has no effect on kidney hypertrophy, blood pressur, podocyte loss, glomerular fibrosis in diabetic spontaneously hypertensive rats (SHR). However, CC-930 reduced the levels of ccl2 mRNA in diabetic kidneys[4].
References:
[1]. Plantevin Krenitsky V, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R, Albers R, Hegde S, D'Sidocky N, Sapienza J et al: Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett, 22(3):1433-1438.
[2]. Waetzig V, Herdegen T: Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 2005, 26(9):455-461.
[3]. Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, Palumbo K, Horn A, Akhmetshina A, Beyer C et al: Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis, 71(5):737-745.
[4]. Lim AK, Ma FY, Nikolic-Paterson DJ, Ozols E, Young MJ, Bennett BL, Friedman GC, Tesch GH: Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats. Am J Nephrol, 34(4):337-346.
- ML 348
Catalog No.:BCC5611
CAS No.:899713-86-1
- A 438079
Catalog No.:BCC1316
CAS No.:899507-36-9
- Platycoside K
Catalog No.:BCN3242
CAS No.:899447-64-4
- A 438079 hydrochloride
Catalog No.:BCC1317
CAS No.:899431-18-6
- Gymnoside III
Catalog No.:BCN8218
CAS No.:899430-03-6
- Beta-Carboline-1-propanoic acid
Catalog No.:BCN5805
CAS No.:89915-39-9
- 3-O-Acetyl-alpha-boswellic acid
Catalog No.:BCN2671
CAS No.:89913-60-0
- 3-Epichromolaenide
Catalog No.:BCN7241
CAS No.:89913-53-1
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride
Catalog No.:BCC8647
CAS No.:898543-06-1
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
- Esculentoside D
Catalog No.:BCN5013
CAS No.:89808-50-4
- YS-035 hydrochloride
Catalog No.:BCC6639
CAS No.:89805-39-0
- 3-Nitro-1-(4-octylphenyl)-1-propanone
Catalog No.:BCN2250
CAS No.:899822-97-0
- 3-(Hydroxymethyl)-3-nitro-1-(4-octylphenyl)-1,4-butanediol
Catalog No.:BCN1313
CAS No.:899822-99-2
- Salicyl alcohol
Catalog No.:BCN4442
CAS No.:90-01-7
- Guaiacol
Catalog No.:BCN8311
CAS No.:90-05-1
- 1-Naphthol
Catalog No.:BCC8473
CAS No.:90-15-3
- beta-Rhamnocitrin
Catalog No.:BCN3293
CAS No.:90-19-7
- Xanthoxylin
Catalog No.:BCN4443
CAS No.:90-24-4
- 4-Methylumbelliferone
Catalog No.:BCN2563
CAS No.:90-33-5
- Xanthone
Catalog No.:BCC6493
CAS No.:90-47-1
- 3,4,5-Trimethoxycinnamic acid
Catalog No.:BCN5030
CAS No.:90-50-6
- 6-Amino-4-hydroxy-2-naphthalenesulfonic acid
Catalog No.:BCC8761
CAS No.:90-51-7
- Lobelin
Catalog No.:BCN2157
CAS No.:90-69-7
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.[Pubmed:22244937]
Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8.
In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors. Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930) as a development candidate, which is currently in Phase II clinical trial for IPF.